AU - Bubna, Aditya TI - Rituximab in dermatology: Revisited PT - REVI DP - 2020 Jan 1 TA - Indian Journal of Drugs in Dermatology PG - 5-12 VI - 6 IP - 1 4099- https://www.ijdd.in/article.asp?issn=2455-3972;year=2020;volume=6;issue=1;spage=5;epage=12;aulast=Bubna;type=0 4100- https://www.ijdd.in/article.asp?issn=2455-3972;year=2020;volume=6;issue=1;spage=5;epage=12;aulast=Bubna AB - Rituximab (RTX) is a specific mouse and human chimeric monoclonal antibody that has found to have numerous applications in dermatology. Though initially approved by the US FDA for treating rheumatoid arthritis and non-Hodgkin's lymphoma; currently its approval has extended to involve the pemphigus group of disorders; both as a first line drug as well as a therapeutic strategy for recalcitrant cases of pemphigus, unresponsive to conventional therapy. Apart from pemphigus, there have been a number of cutaneous disorders where rituximab has been found to be useful. This review will give a bird's eye view of the applications of rituximab in dermatology.